Effect of Anti-B7-1 or Anti-B7-2 F(ab)2Treatment on the Lysis of BW Targets by IL-2 A-LAK and IL-2/IL-12 A-LAK Effector Cells
| Target Cells . | . | BW-Li(B7-1) . | BW-Li(B7-2) . | ||||
|---|---|---|---|---|---|---|---|
| Treatment . | . | None . | AntiB7-1* . | Control* . | None . | AntiB7-2* . | Control* . |
| Effector cells . | E:T . | % Increase† . | % Inhibition‡ . | % Increase† . | % Inhibition‡ . | ||
| IL-2 LAK | 5 | 0 | — | — | 0 | — | — |
| 10 | 266 | 74 | 0 | 207 | 32 | 0 | |
| 20 | 179 | 80 | 1 | 134 | 65 | 16 | |
| IL-2/IL-12 LAK | 5 | 177 | 100 | 0 | 206 | 75 | 0 |
| 10 | 309 | 68 | 0 | 259 | 52 | 7 | |
| 20 | 116 | 80 | 0 | 181 | 100 | 25 | |
| Target Cells . | . | BW-Li(B7-1) . | BW-Li(B7-2) . | ||||
|---|---|---|---|---|---|---|---|
| Treatment . | . | None . | AntiB7-1* . | Control* . | None . | AntiB7-2* . | Control* . |
| Effector cells . | E:T . | % Increase† . | % Inhibition‡ . | % Increase† . | % Inhibition‡ . | ||
| IL-2 LAK | 5 | 0 | — | — | 0 | — | — |
| 10 | 266 | 74 | 0 | 207 | 32 | 0 | |
| 20 | 179 | 80 | 1 | 134 | 65 | 16 | |
| IL-2/IL-12 LAK | 5 | 177 | 100 | 0 | 206 | 75 | 0 |
| 10 | 309 | 68 | 0 | 259 | 52 | 7 | |
| 20 | 116 | 80 | 0 | 181 | 100 | 25 | |
*Targets were treated during 30 minutes with anti-B7-1, anti-B7-2, and isotype control F(ab)2 fragments of antibodies before inclusion in 111In-release assay (see Materials and Methods).
Percent increase in the specific lysis of BW-Li transfected with B7-1 or B7-2 as compared with nontransfected cells.
Percent inhibition of the B7-1/B7-2–induced increase in LAK-mediated lysis of BW-Li variants due to B7-1, B7-2, or isotype control F(ab)2 antibody treatment.